Magdalena Kegel,  —

Cystic Fibrosis Foundation Therapeutics (CFFT) will increase funding to support Spyryx Biosciences‘ Phase 2 trial assessing SPX-101 in people with cystic fibrosis. The funding is part of an award Spyryx received in 2015 from CFFT, the Cystic Fibrosis Foundation‘s…

So-called silent gene mutations in the cystic fibrosis (CF)-causing CFTR gene are not necessarily silent at all. A research team discovered that one such mutation also causes the resulting protein to have a poor function. The insights put the spotlight on the complexity of CF genetic causes, but also advances…

The U.S. Food and Drug Administration (FDA) has expanded its approval of Kalydeco (ivacaftor) to include cystic fibrosis (CF) patients with one of 23 additional rare mutations — more than tripling the number of mutations the oral drug may be used to treat from 10 to 33. But the decision’s…

Yet another consequence of lung infections with the bacterium Pseudomonas (P.) aeruginosa in cystic fibrosis (CF) patients has been discovered, researchers report. But this time, it may be to the disadvantage of the microbe. Another type of bacteria, normally only present on teeth, can hijack Pseudomonas factors to prevent its…

Doctors may soon diagnose cystic fibrosis (CF) with the help of a wristband, thanks to a new wearable sweat analysis tool that measures the molecular constituents of sweat, such as chloride ions and glucose. The device is an upgrade from earlier sweat analysis tools that required patients to be still for up to…

A small proof-of-concept Phase 2 trial (NCT02722122) of alidornase alfa showed that the therapy improved lung function in patients with cystic fibrosis (CF), according to its developer Protalix BioTherapeutics. In addition to making breathing difficult, the thick mucus in CF patients’ airways makes ideal growth conditions for many…

Swiss-based Polyphor has secured financing for late-stage development of Murepavadin (POL7080), an antibiotic targeting a bacteria that often infects the airways of cystic fibrosis (CF) patients. A hallmark of the therapy is that it goes after antibiotic-resistant strains of Pseudomonas aeruginosa, which infects not just MS patients, but people with other…

A pancreatic enzyme replacement product that is not derived from pigs — Sollpura (liprotamase) — was as good at maintaining the height and weight of cystic fibrosis (CF) patients as a pig-derived product, according to a clinical trial. The information came from the extension period of Anthera’s Phase 3…

Mucus proteins that fail to achieve the correct structure cause airway secretions to become thick and sticky in patients with cystic fibrosis (CF), leading to the well-known symptoms of the disease, according to a study. The reason the proteins fail to assume the shape that’s seen in healthy people is simple,…

Cystic fibrosis (CF) patients have a poorer diversity of gut bacteria than healthy people, and it gets worse as the disease progresses, an Irish study indicates. In addition, patients with severe lung impairment have significantly fewer bacterial species in their gut than those with mild lung problems, researchers found. Because frequent intravenous antibiotic…